Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011;1(2):204-14.
Epub 2011 Sep 22.

C-MOPP: the forgotten regimen plus Rituximab for untreated and relapsed follicular lymphoma

Mark J Fesler, Medhat Osman, James Glauber, Paul J Petruska

C-MOPP: the forgotten regimen plus Rituximab for untreated and relapsed follicular lymphoma

Mark J Fesler et al. Am J Blood Res. 2011.

Abstract

C-MOPP is a chemotherapy regimen for the treatment of Non-Hodgkin lymphoma (NHL). Because rituximab improves results in B-cell NHL, we added rituximab to C-MOPP, giving it the term C-MOPP-R. We retrospectively report the results of C-MOPP-R treatment for follicular lymphoma at Saint Louis University Cancer Center from 2000-2009. Treatment response was assessed with fusion PET/CT using International Harmonization Project Criteria and toxicity using National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. Thirty-seven patients with follicular lymphoma were treated at our institution with C-MOPP-R. The complete response rate was ninety-four percent and sixty-eight percent in untreated and relapsed patients, respectively. The median progression-free and overall survivals were not reached with median observation time of 34 months. Development of peripheral neuropathy required truncation of planned vincristine dosing in nearly half of patients. We believe that C-MOPP-R results in excellent response rates, progression-free, and overall survival for untreated and relapsed follicular lymphoma and capped vincristine dosing is essential to optimize safety.

Keywords: Lymphoma; Non-Hodgkin; Positron Emission Tomography; antibodies; antineoplastic agents; monoclonal.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schema of the C-MOPP-R chemotherapy program.
Figure 2
Figure 2
Progression-Free Survival of the entire cohort treated with C-MOPP-R.
Figure 3
Figure 3
Overall Survival of the entire cohort treated with C-MOPP-R.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Morgenfeld MC, Pavlovsky A, Suarez A, Somoza N, Pavlovsky S, Palau M, Barros CA. Combined cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) therapy of malignant lymphoma. Cancer. 1975;36:1241–1249. - PubMed
    1. Longo DL, Young RC, Hubbard SM, Wesley M, Fisher RI, Jaffe E, Berard C, DeVita VT., Jr Prolonged initial remission in patients with nodular mixed lymphoma. Ann Intern Med. 1984;100:651–656. - PubMed
    1. Ezdinli EZ, Costello WG, Silverstein MN, Berard C, Hartsock RJ, Sokal JE. Moderate versus intensive chemotherapy of prognostically favorable non-Hodgkin's lymphoma. Cancer. 1980;46:29–33. - PubMed
    1. Glick JH, Barnes JM, Ezdinli EZ, Berard CW, Orlow EL, Bennett JM. Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy. Blood. 1981;58:920–925. - PubMed
    1. Liang R, Todd D, Chan TK, Chiu E, Lie A, Ho F. COPP chemotherapy for elderly patients with intermediate and high grade non-Hodgkin's lymphoma. Hematol Oncol. 1993;11:43–50. - PubMed

LinkOut - more resources